Loading
Cancer Cells and Metastasis / Immune Cells in Cancer · Journal article
Journal of Translational Medicine · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes current mechanistic and preclinical evidence on cancer-associated fibroblasts (CAFs) as drivers of immune exclusion, therapy resistance, and poor outcome in osteosarcoma. The authors propose several translational directions—including NADPH oxidase 4 inhibition, focal adhesion kinase-related stromal targeting, and sequence-based chemoimmunotherapy—but emphasize that these require further validation through osteosarcoma-specific preclinical models, biomarker development, and clinical testing.
Narrative review. Literature on cancer-associated fibroblasts in osteosarcoma; no original patient enrollment.
CAFs regulate immune exclusion and therapy resistance through matrix deposition, cytokine signaling, exosome communication, and metabolic competition in osteosarcoma Distinct stromal contexts exist in primary osteosarcoma versus pulmonary metastases, with differential CAF states identified by single-cell and spatial profiling NADPH oxidase 4 inhibition, focal adhesion kinase-related stromal targeting, and sequence-based chemoimmunotherapy are identified as key translational directions requiring validation
No quantitative evidence on safety, efficacy, or biomarker performance of proposed therapies in any osteosarcoma cohort
Clinicians should recognize CAFs as a microenvironment target for sensitizing chemotherapy and immunotherapy in osteosarcoma; however, no validated CAF biomarkers or stromal-directed therapies are yet standard-of-care. Translation requires osteosarcoma-specific preclinical validation and biomarker-guided patient stratification before clinical trials.
This is a narrative review synthesizing mechanistic and preclinical evidence on CAF biology in osteosarcoma, proposing translational directions without clinical trial data or validated biomarkers.
As stated by the source record.
Clinicians should recognize CAFs as a microenvironment target for sensitizing chemotherapy and immunotherapy in osteosarcoma; however, no validated CAF biomarkers or stromal-directed therapies are yet standard-of-care. Translation requires osteosarcoma-specific preclinical validation and biomarker-guided patient stratification before clinical trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Background Osteosarcoma remains a highly aggressive bone malignancy with limited therapeutic progress in metastatic and treatment-refractory disease. Beyond tumor-intrinsic drivers, the tumor microenvironment has emerged as a critical determinant of immune escape, therapeutic resistance, and poor clinical outcome. Among stromal components, cancer-associated fibroblasts (CAFs) are increasingly recognized as central regulators of extracellular matrix remodeling, immune suppression, and treatment failure; however, their specific translational relevance in osteosarcoma remains incompletely defined. Main body In this review, we synthesize current evidence on CAF-mediated immune exclusion, immune suppression, and therapy resistance in osteosarcoma and organize the field into an evidence-stratified translational framework. We discuss how CAFs shape a treatment-refractory microenvironment through matrix deposition and stiffening, cytokine and chemokine signaling, exosome-mediated communication, and metabolic competition, while emphasizing the distinct stromal contexts of primary osteosarcoma and pulmonary metastases. We further summarize emerging CAF states and stromal-immune interaction programs identified by single-cell and spatial profiling, with emphasis on their implications for T-cell exclusion, myeloid reprogramming, chemotherapy resistance and immunotherapy response. Therapeutically, we evaluate CAF normalization, matrix-targeted intervention, local delivery strategies, and rational combination approaches, highlighting NADPH oxidase 4 inhibition, focal adhesion kinase-related stromal targeting and sequence-based chemoimmunotherapy as key translational directions that require further validation through delivery feasibility, safety assessment, and biomarker-guided patient stratification. Conclusions Current evidence supports CAF-directed intervention in osteosarcoma primarily as a microenvironment-modulating and treatment-sensitizing strategy rather than as a stand-alone cytotoxic approach. Clinical translation will require osteosarcoma-specific validation in bone-relevant and immunocompetent models, multiplex CAF biomarker panels compatible with formalin-fixed, paraffin-embedded tissue, and rational treatment-sequencing strategies that integrate stromal normalization with chemotherapy, surgery, and immunotherapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.